Benzinga's Top #PreMarket Losers

Athersys ATHX dropped 52.38% to $1.30 in pre-market trading on failed trial results for ulcerative colitis. OncoGenex Pharmaceuticals OGXI shares fell 47.84% to $5.06 in pre-market trading after the company and Teva Pharmaceutical Industries TEVA offered top-line survival results of the Phase III SYNERGY trial for combo with first-line docetaxel/prednisone therapy. POZEN POZN shares dropped 18.84% to $7.41 in pre-market trading following Friday's Complete Response Letter from the FDA. Newmont Mining NEM dipped 5.29% to $25.05 in pre-market trading after the company terminated its merger talks with Barrick Gold ABX.